^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pomalidomide

    i
    Other names: CC 4047, CDC 394, CC-4047 , CDC-394, CC4047, CDC394
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor
    Related drugs:
    1d
    MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=166, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Apr 2027 --> Oct 2027
    Trial completion date
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs)
    2d
    PEACH: Pomalidomide as an Immune-enhancing Agent for the Control of HIV (clinicaltrials.gov)
    P1/2, N=32, Active, not recruiting, University of Aarhus | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    pomalidomide • aspirin
    3d
    DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1/2, N=208, Active, not recruiting, GlaxoSmithKline | Phase classification: P2 --> P1/2
    Phase classification
    |
    lenalidomide • Jemperli (dostarlimab-gxly) • dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998
    3d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    4d
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=260, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • TQB2934
    4d
    Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer. (PubMed, J Proteome Res)
    Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.
    Journal
    |
    IKZF2 (IKAROS family zinc finger 2)
    |
    pomalidomide • iberdomide (CC-220) • mezigdomide (CC-92480)
    5d
    STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)
    P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    6d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=38, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    7d
    A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatment. (PubMed, Discov Oncol)
    PROTAC LNPs were synthesized by modifying F1324 and pomalidomide aptamers onto LNPs via a covalent chemical reaction in a certain proportion...Overall, we developed a PROTAC that exhibited persistent and excellent BCL6 degradation ability in DLBCL, with an excellent safety profile. Thus, our BCL6 degrader provides a complementary approach to existing clinical‑stage candidates.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6)
    |
    pomalidomide
    8d
    QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P2 trial
    |
    lenalidomide • dexamethasone • pomalidomide • dexamethasone injection
    10d
    DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (clinicaltrials.gov)
    P1/2, N=153, Recruiting, GlaxoSmithKline | N=32 --> 153
    Enrollment change
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    10d
    MAGNETISMM-5: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (clinicaltrials.gov)
    P3, N=944, Recruiting, Pfizer | N=361 --> 944
    Enrollment change
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)